Home > Tables & Figures

Tables & Figures


Table 3.6 Selected clinical trials conducted on licensed antifungals

Antifungal prophylaxis Neutropenic fever Invasive aspergillosis Candidaemia or invasive candidiasis Oesophageal candidiasis
Voriconazole vs. placebo (182) Micafungin vs caspofungin (183) Posaconazole vs liposomal amphotericin B ± caspofungin (184) Caspofungin vs amphotericin B (172);
Caspofungin vs amphotericin B in newborn infants (185)
Caspofungin vs amphotericin B (186–187)
Micafungin vs fluconazole (188); Micafungin vs fluconazole (189);
Micafungin vs fluconazole, liposomal amphotericin B or caspofungin post-liver-transplant (190)
Caspofungin vs liposomal amphotericin B (191); Caspofungin vs liposomal amphotericin B (192) Voriconazole vs amphotericin B (173,193) Caspofungin (standard vs high dose) (194) Caspofungin vs fluconazole (195)
Itraconazole vs fluconazole (196–197) Voriconazole vs liposomal amphotericin B (198) Liposomal amphotericin B (standard dose vs high loading dose)(199) Anidulafungin vs fluconazole (200);
Anidulafungin vs fluconazole in critically ill (201)
Anidulafungin vs fluconazole (202)
Posaconazole vs fluconazole or itraconazole (203–205) Itraconazole vs amphotericin B (206–207) Isavuconazole vs voriconazole (for invasive mould disease) (208) Micafungin vs caspofungin (177) Micafungin vs fluconazole (209–210)
Voriconazole/ posaconazole vs fluconazole/ itraconazole in AML/MDS undergoing chemotherapy (211);
Voriconazole vs itraconazole in post allogeneic HSCT (212);
Voriconazole vs fluconazole in post allogeneic HSCT (213)
Different amphotericin B formulations (214–215) Voriconazole and anidulafungin vs voriconazole monotherapy (216) Micafungin vs liposomal amphotericin B (217–219) Voriconazole vs fluconazole (220)
Aerosolized liposomal amphotericin B vs placebo inhalation (221) Micafungin vs itraconazole (222)   Voriconazole vs amphotericin B followed by fluconazole (223) Isavuconazole vs fluconazole (224)
Voriconazole vs low dose amphotericin B in paediatric acute leukaemia induction (225) Immediate voriconazole vs deferred placebo (226)   Micafungin vs voriconazole in kidney transplant recipients (227)  
Anidulafungin vs fluconazole in high-risk liver transplant patients (228)     Preemptive micafungin following gastrointestinal surgery (229)  
Caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis (230)     Caspofungin vs micafungin (231)  



AML, acute myelogenous leukaemia
HSCT, haematopoietic stem cell transplantation
MDS, myelodysplastic syndromes
Agent with superior results for some outcomes is underlined.